NEW YORK, April 12, 2019 (GLOBE NEWSWIRE) --
AXIMÂ® Biotechnologies, Inc.
(âAXIMâ) (âthe Companyâ) (âAXIMÂ® Biotechâ) (AXIM), a world leader in cannabinoid research and
development, today announced the companyâs Chief Technology Officer
Lekhram Changoer will be speaking at the âBelieveâ National
Convention held by KannawayÂ®, the first hemp lifestyle
network to offer cannabidiol (âCBDâ) hemp botanical products, on
April 13, 2019 in San Diego.
Changoer will present on the science behind the
companyâs chewing gum as an effective delivery mechanism for
cannabinoids, CBD in particular. AXIM's research has shown that its
proprietary encapsulation methodology, combined with patented
chewing gum delivery system, causes CBD to be effectively released
from the chewing gum into the oral cavity to increase CBD presence
for absorption through the oral mucosa. AXIM holds exclusive
licenses to two patents on chewing gums containing cannabinoids,
including CBD and tetrahydrocannabinol (âTHCâ).
âWeâre looking forward to the âBelieveâ event and
to educating the Kannaway community,â said Lekhram Changoer, Chief
Technology Officer of AXIMÂ® Biotech. âOur encapsulation
technology gives us an opportunity to be a key player in the hemp
market and Kannaway is a great partner to reach consumers who are
interested in hemp and its wide-ranging benefits. Iâm excited to
share AXIMâs knowledge and key findings in chewing gum as a
delivery mechanism for CBD.â
In February 2019, KannawayÂ®announced a significant
purchase order from AXIMÂ® Biotech for
CanChew+â¢, a cannabinoid-based chewing gum containing 50
mg of full-spectrum hemp oil and 10 mg of CBD per piece.
âAXIM looks forward to expanding the reach of our
consumer-directed product, CanChew+â¢, through this
purchase order with KannawayÂ® as the company distributes
to thousands of consumers around the world,â said John W.
Huemoeller II, Chief Executive Officer of AXIMÂ® Biotech.
âWe will now be able to reach more people interested in the
benefits of hemp with our CBD gum.â
To learn more about AXIMÂ®
Biotechnologies, Inc., visit http://aximbiotech.com/.
About AXIMÂ® Biotechnologies
AXIMÂ® Biotechnologies, Inc. (AXIM) is a world leader in the
research and development of cannabinoid-based pharmaceutical and
nutraceutical products. Along with building a robust intellectual
property portfolio, AXIM is focused on clinical development
programs that bring more efficacy and/or lower side effects than
existing alternatives and require small to medium budgets and
timelines to bring to market which presents a high added-value to
the pharmaceutical field.
AXIM's flagship products include MedChewÂ® with
dronabinol, which is planned to undergo a bioequivalence study to
fast track through FDA as an alternative to approved Marinol;
MedChewÂ® RL, which is planned to undergo clinical trials for
treatment of restless leg syndrome; and MedChewÂ® Rx, a combination
cannabidiol (CBD)/tetrahydrocannabinol (THC) functional,
controlled-release chewing gum that is planned to undergo clinical
trials for the treatment of pain and spasticity associated with
Multiple Sclerosis (MS). For more information, please visit
This press release may contain certain forward-looking statements
and information, as defined within the meaning of Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934 and is subject to the Safe Harbor created by
those sections. This material contains statements about expected
future events and/or financial results that are forward-looking in
nature and subject to risks and uncertainties. Such forward-looking
statements by definition involve risks, uncertainties and other
factors, which may cause the actual results, performance or
achievements of AXIM Biotechnologies, Inc. to be materially
different from the statements made herein.
AXIMÂ® Biotechnologies does not sell or distribute any products that
are in violation of the United States Controlled Substances Act
Public Relations Contact:
Chief Executive Officer
Corporate Contact Info:
North American Address:
45 Rockefeller Plaza, 20th Fl.
New York, NY 10111, USA
P. 844 294 6246
Industrieweg 40, Unit B4
3401 MA IJsselstein